Archivio Comunicati Stampa 2014
Boston Scientific Receives CE Mark For The Vercise™ Deep Brain Stimulation (DBS) System For Treating Patients With Tremor [EN] - Sep 17, 2014
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the Vercise™ Deep Brain Stimulation (DBS) System for the treatment of tremor, including ...
Boston Scientific Announces One-Year Results In The VANTAGE Clinical Study Evaluating The Vercise™ DBS System [EN] - Jun 11, 2014
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant ...
Clinical Study Results Demonstrate Therapeutic Advantages Of The Boston Scientific Vercise™ DBS System For Patients With Parkinson's Disease [EN] - Jun 10, 2014
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation ...
First Patient Enrolled In Clinical Registry Assessing Boston Scientific Vercise Deep Brain Stimulation System In Patients With Parkinsons Disease [EN] - Apr 10, 2014
Boston Scientific Corporation (NYSE: BSX) has enrolled the first patient in a new registry to evaluate clinical outcomes and the economic value of ...
Dystonia Europe And The European Parkinson’s Disease Association (Epda) Partner With Boston Scientific In Advancing Parkinson’s And Dystonia Care [EN] - Feb 24, 2014
Dystonia Europe (DE) and The European Parkinson’s Disease Association (EPDA) announced today that they are collaborating with Boston Scientific ...
Contatti media
Alessandra Gelera
Economia Sanitaria e Affari Istituzionali
+39 0226 9831
Italy.PublicAffairs@bsci.com
Daniela Colombo
Rapporti con la stampa
+39 333 5286 950
info@colombodaniela.it
Per tutte le altre domande o richieste, visitate questa pagina, dove troverete tutti gli indirizzi e numeri di telefono utili per contattare Boston Scientific.
Profilo dell'azienda